Track topics on Twitter Track topics that are important to you
The US Food and Drug Administration (FDA) has approved a targeted therapy, Besponsa (inotuzumab ozogamicin), for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL).
Original Article: FDA approves treatment for rapidly progressing type of cancerNEXT ARTICLE
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...